{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T01:16:12Z","timestamp":1788138972945,"version":"build-2803163510"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":75,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Malignant peripheral nerve sheath tumour (MPNST) is a rare, aggressive sarcoma with high mortality. MPNST can develop sporadically, after radiation therapy or in association with neurofibromatosis type 1 (NF1). The treatment is challenging especially if surgical removal is not possible. NF1 is an autosomal-dominant genetic disorder most often caused by a germline pathogenic variant in the\n                      <jats:italic>NF1<\/jats:italic>\n                      gene and in rare cases a deletion of the\n                      <jats:italic>NF1<\/jats:italic>\n                      gene. Patients with NF1 have a higher risk of developing several different cancers, of which MPNST is one of the most frequent. MPNST in individuals with NF1 often presents with large MPNST which are often not accessible for surgery. Several studies have shown that patients with NF1-associated MPNST (nfMPNST) have an overall inferior survival than those with sporadic MPNST (sMPNST). Despite this, NF1 status alone may not be a causative factor for poor prognosis, which might rather be due to the incidence of larger tumours, which are more challenging to resect in toto.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>A systematic research protocol was made using the PRISMA-P model and the review question and inclusion and exclusion criteria were defined using the PICO model. The study characteristics defined by PICO include patients with NF1 as the population of interest. The development of MPNST was considered as the intervention, patients with sMPNST were chosen for comparison and the primary outcome of interest was survival. The literature search was performed on 12 October 2024 and 4,394 studies were eligible for screening, of which 36 studies were included in this study. Meta-analysis of eight studies found NF1 status to be a risk factor for the survival of MPNST. The reported survival rates varied between studies, but the 5-year overall survival (OS) remained poor in general, Awith 15 studies showing a significantly inferior survival for nfMPNST. Only four studies have a worse survival for sMPNST, but none with a significant difference.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The findings in this systematic review and meta-analysis of 36 studies indicates that patients with nfMPNST have a worse survival compared to sMPNST.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-026-04460-w","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T17:34:20Z","timestamp":1781717660000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Survival and prognosis of neurofibromatosis type 1-associated malignant peripheral nerve sheath tumours: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"21","author":[{"given":"Mette M\u00f8ller","family":"Handrup","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ninna","family":"Aggerholm-Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stine Bogetofte","family":"Thomasen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma Hyldgaard","family":"Olesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3815-0613","authenticated-orcid":false,"given":"Cecilie","family":"Ejerskov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"4460_CR1","doi-asserted-by":"crossref","unstructured":"Ducatman BS, Scheithauer BW, Piepgras DG, Reiman HM, Ilstrup DM. Malignant peripheral nerve sheath tumors a clinicopathologic study of 120 cases. 2006.","DOI":"10.1002\/1097-0142(19860515)57:10<2006::AID-CNCR2820571022>3.0.CO;2-6"},{"key":"4460_CR2","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1007\/BF02303627","volume":"2","author":"JN Vauthey","year":"1995","unstructured":"Vauthey JN, Woodruff JM, Brennan MF. Extremity malignant peripheral nerve sheath tumors (neurogenic sarcomas): A 10-year experience. Ann Surg Oncol. 1995;2:126\u201331.","journal-title":"Ann Surg Oncol"},{"key":"4460_CR3","unstructured":"Ferner RE, Gutmann DH. International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis 1 1. Cancer Res. 2002."},{"key":"4460_CR4","doi-asserted-by":"crossref","unstructured":"LM ES, KB TJN, BM S. T, Y L, Gender dimorphism and age of onset in malignant peripheral nerve sheath tumor preclinical models and human patients. BMC Cancer. 2014;14.","DOI":"10.1186\/1471-2407-14-827"},{"key":"4460_CR5","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1007\/s11912-009-0045-z","volume":"11","author":"BC Widemann","year":"2009","unstructured":"Widemann BC. Current Status of Sporadic and Neurofibromatosis Type 1\u2013Associated Malignant Peripheral Nerve Sheath Tumors. Curr Oncol Rep. 2009;11:322.","journal-title":"Curr Oncol Rep"},{"key":"4460_CR6","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S0360-3016(98)00223-5","volume":"42","author":"WW Wong","year":"1998","unstructured":"Wong WW, Hirose T, Scheithauer BW, Schild SE, Gunderson LL. Malignant peripheral nerve sheath tumor: analysis of treatment outcome. Int J Radiation Oncology*Biology*Physics. 1998;42:351\u201360.","journal-title":"Int J Radiation Oncology*Biology*Physics"},{"key":"4460_CR7","unstructured":"Wanebo JE, Malik JM, Vandenberg SR, Wanebo HJ, Driesen N, Persing JA. Malignant peripheral nerve sheath tumors a clinicopathologic study of 28 cases."},{"key":"4460_CR8","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/978-3-642-32864-0_29","volume":"9783642328","author":"H Meany","year":"2012","unstructured":"Meany H, Widemann BC, Ratner N. Malignant Peripheral Nerve Sheath Tumors: Prognostic and Diagnostic Markers and Therapeutic Targets. Neurofibromatosis Type 1: Mol Cell Biology. 2012;9783642328:445\u201367.","journal-title":"Neurofibromatosis Type 1: Mol Cell Biology"},{"key":"4460_CR9","unstructured":"University JH. OMIM. MIM No. #162200, Neurofibromatosis, type 1; Online Mendelian Inheritance in Man, OMIM. Baltimore. 2018."},{"key":"4460_CR10","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/ajmg.a.33139","volume":"152A","author":"DG Evans","year":"2010","unstructured":"Evans DG, Howard E, Giblin C, Clancy T, Spencer H, Huson SM, et al. Birth incidence and prevalence of tumor-prone syndromes: Estimates from a UK family genetic register service. Am J Med Genet A. 2010;152A:327\u201332.","journal-title":"Am J Med Genet A"},{"key":"4460_CR11","doi-asserted-by":"publisher","unstructured":"Gutmann DH, Ferner RE, Listernick RH, Korf BR, Wolters PL, Johnson KJ. Neurofibromatosis type 1. Nat Rev Dis Primers [Internet]. 2017;3:1\u201318. Available from: https:\/\/doi.org\/10.1038\/nrdp.2017.4.","DOI":"10.1038\/nrdp.2017.4"},{"key":"4460_CR12","unstructured":"James AW, Shurell E, Singh A, Dry SM, Eilber FC. Malignant peripheral nerve sheath tumor."},{"key":"4460_CR13","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1212\/01.wnl.0000250332.89420.e6","volume":"68","author":"E Dombi","year":"2007","unstructured":"Dombi E, Solomon J, Gillespie AJ, Fox E, Balis FM, Patronas N, et al. NF1 plexiform neurofibroma growth rate by volumetric MRI. Neurology. 2007;68:643\u20137.","journal-title":"Neurology"},{"key":"4460_CR14","doi-asserted-by":"crossref","unstructured":"Nguyen R, Dombi E, Widemann BC, Solomon J, Fuensterer C, Kluwe L, et al. Growth dynamics of plexiform neurofibromas: A retrospective cohort study of 201 patients with neurofibromatosis 1. Orphanet J Rare Dis. 2012;7.","DOI":"10.1186\/1750-1172-7-75"},{"key":"4460_CR15","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/PAP.0000000000000197","volume":"25","author":"JF Longo","year":"2018","unstructured":"Longo JF, Weber SM, Turner-Ivey BP, Carroll SL. Recent advances in the diagnosis and pathogenesis of neurofibromatosis type 1 (NF1)-associated peripheral nervous system neoplasms. Adv Anat Pathol. 2018;25:353\u201368.","journal-title":"Adv Anat Pathol"},{"key":"4460_CR16","doi-asserted-by":"crossref","unstructured":"Kolberg M, H\u00f8land M, Agesen TH, Brekke HR, Liest\u00f8l K, Hall KS, et al. Survival meta-analyses for >\u20091800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1. Neuro Oncol. Oxford University Press. 2013:135\u201347.","DOI":"10.1093\/neuonc\/nos287"},{"key":"4460_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12957-020-02036-x","volume":"18","author":"Z Cai","year":"2020","unstructured":"Cai Z, Tang X, Liang H, Yang R, Yan T, Guo W. Prognosis and risk factors for malignant peripheral nerve sheath tumor: A systematic review and meta-analysis. World J Surg Oncol. 2020;18:1\u201312.","journal-title":"World J Surg Oncol"},{"key":"4460_CR18","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s40487-022-00213-4","volume":"11","author":"C Ejerskov","year":"2023","unstructured":"Ejerskov C, Farholt S, Nielsen FSK, Berg I, Thomasen SB, Udupi A, et al. Clinical Characteristics and Management of Children and Adults with Neurofibromatosis Type 1 and Plexiform Neurofibromas in Denmark: A Nationwide Study. Oncol Ther. 2023;11:97\u2013110.","journal-title":"Oncol Ther"},{"key":"4460_CR19","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1002\/cncr.22098","volume":"107","author":"M Anghileri","year":"2006","unstructured":"Anghileri M, Miceli R, Fiore M, Mariani L, Ferrari A, Mussi C, et al. Malignant peripheral nerve sheath tumors: Prognostic factors and survival in a series of patients treated at a single institution. Cancer. 2006;107:1065\u201374.","journal-title":"Cancer"},{"key":"4460_CR20","first-page":"e112","volume":"46","author":"MJ Page","year":"2022","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. [The PRISMA 2020 statement: an updated guideline for reporting systematic reviewsDeclaraci\u00f3n PRISMA 2020: una gu\u00eda actualizada para la publicaci\u00f3n de revisiones sistem\u00e1ticas]. Rev Panam Salud Publica. 2022;46:e112.","journal-title":"Rev Panam Salud Publica"},{"key":"4460_CR21","unstructured":"Defining your review question - Systematic Reviews - Research Guide. - Help and Support at Murdoch University. https:\/\/libguides.murdoch.edu.au\/systematic\/defining. Accessed 24 January 2025."},{"key":"4460_CR22","unstructured":"Ottawa Hospital Research Institute. https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp. Accessed January 24 2025."},{"key":"4460_CR23","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1002\/gcc.23106","volume":"62","author":"NP Agaram","year":"2023","unstructured":"Agaram NP, Wexler LH, Chi P, Antonescu CR. Malignant peripheral nerve sheath tumor in children: A clinicopathologic and molecular study with parallels to the adult counterpart. Genes Chromosomes Cancer. 2023;62:131\u20138.","journal-title":"Genes Chromosomes Cancer"},{"key":"4460_CR24","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1002\/path.1998","volume":"209","author":"CT Storlazzi","year":"2006","unstructured":"Storlazzi CT, Brekke HR, Mandahl N, Brosj\u00f6 O, Smeland S, Lothe RA, et al. Identification of a novel amplicon at distal 17q containing the BIRC5\/SURVIVIN gene in malignant peripheral nerve sheath tumours. J Pathol. 2006;209:492\u2013500.","journal-title":"J Pathol"},{"key":"4460_CR25","doi-asserted-by":"publisher","first-page":"8422","DOI":"10.1200\/JCO.2005.01.4886","volume":"23","author":"M Carli","year":"2005","unstructured":"Carli M, Ferrari A, Mattke A, Zanetti I, Casanova M, Bisogno G, et al. Pediatric malignant peripheral nerve sheath tumor: the Italian and German soft tissue sarcoma cooperative group. J Clin Oncol. 2005;23:8422\u201330.","journal-title":"J Clin Oncol"},{"key":"4460_CR26","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1007\/BF02307086","volume":"2","author":"JM deCou","year":"1995","unstructured":"deCou JM, Rao BN, Parham DM, Lobe TE, Bowman L, Pappo AS, et al. Malignant peripheral nerve sheath tumors: the St. Jude Children\u2019s Research Hospital experience. Ann Surg Oncol. 1995;2:524\u20139.","journal-title":"Ann Surg Oncol"},{"key":"4460_CR27","doi-asserted-by":"publisher","first-page":"3771","DOI":"10.1158\/1078-0432.CCR-10-2393","volume":"17","author":"M Endo","year":"2011","unstructured":"Endo M, Kobayashi C, Setsu N, Takahashi Y, Kohashi K, Yamamoto H, et al. Prognostic significance of p14ARF, p15INK4b, and p16INK4a inactivation in malignant peripheral nerve sheath tumors. Clin Cancer Res. 2011;17:3771\u201382.","journal-title":"Clin Cancer Res"},{"key":"4460_CR28","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1136\/jmg.39.5.311","volume":"39","author":"DGR Evans","year":"2002","unstructured":"Evans DGR, Baser ME, McGaughran J, Sharif S, Howard E, Moran A. Malignant peripheral nerve sheath tumours in neurofibromatosis. J Med Genet. 2002;39:311\u20134.","journal-title":"J Med Genet"},{"key":"4460_CR29","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1593\/neo.07304","volume":"9","author":"N Holtkamp","year":"2007","unstructured":"Holtkamp N, Atallah I, Okuducu AF, Mucha J, Hartmann C, Mautner VF, et al. MMP-13 and p53 in the progression of malignant peripheral nerve sheath tumors. Neoplasia. 2007;9:671\u20137.","journal-title":"Neoplasia"},{"key":"4460_CR30","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1002\/1097-0142(19900915)66:6<1253::AID-CNCR2820660627>3.0.CO;2-R","volume":"66","author":"RH Hruban","year":"1990","unstructured":"Hruban RH, Shiu MH, Senie RT, Woodruff JM. Malignant peripheral nerve sheath tumors of the buttock and lower extremity. A study of 43 cases. Cancer. 1990;66:1253\u201365.","journal-title":"Cancer"},{"key":"4460_CR31","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s10585-014-9662-5","volume":"31","author":"K Ikuta","year":"2014","unstructured":"Ikuta K, Urakawa H, Kozawa E, Arai E, Zhuo L, Futamura N, et al. Hyaluronan expression as a significant prognostic factor in patients with malignant peripheral nerve sheath tumors. Clin Exp Metastasis. 2014;31:715\u201325.","journal-title":"Clin Exp Metastasis"},{"key":"4460_CR32","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1136\/jmg.2006.048140","volume":"44","author":"JA McCaughan","year":"2007","unstructured":"McCaughan JA, Holloway SM, Davidson R, Lam WW. Further evidence of the increased risk for malignant peripheral nerve sheath tumour from a Scottish cohort of patients with neurofibromatosis type 1. J Med Genet. 2007;44:463\u20136.","journal-title":"J Med Genet"},{"key":"4460_CR33","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1002\/jso.26153","volume":"122","author":"MT Meister","year":"2020","unstructured":"Meister MT, Scheer M, Hallmen E, Stegmaier S, Vokuhl C, von Kalle T, et al. Malignant peripheral nerve sheath tumors in children, adolescents, and young adults: Treatment results of five Cooperative Weichteilsarkom Studiengruppe (CWS) trials and one registry. J Surg Oncol. 2020;122:1337\u201347.","journal-title":"J Surg Oncol"},{"key":"4460_CR34","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1245\/s10434-006-9053-5","volume":"14","author":"K Okada","year":"2007","unstructured":"Okada K, Hasegawa T, Tajino T, Hotta T, Yanagisawa M, Osanai T, et al. Clinical relevance of pathological grades of malignant peripheral nerve sheath tumor: a multi-institution TMTS study of 56 cases in Northern Japan. Ann Surg Oncol. 2007;14:597\u2013604.","journal-title":"Ann Surg Oncol"},{"key":"4460_CR35","doi-asserted-by":"crossref","unstructured":"Porter DE, Prasad V, Foster L, Dall GF, Birch R, Grimer RJ. Survival in malignant peripheral nerve sheath tumours: a comparison between sporadic and neurofibromatosis type 1-associated tumours. Sarcoma. 2009.","DOI":"10.1155\/2009\/756395"},{"key":"4460_CR36","doi-asserted-by":"publisher","first-page":"106","DOI":"10.4103\/jcrt.JCRT_854_19","volume":"17","author":"MR Sharma","year":"2021","unstructured":"Sharma MR, Puj KS, Salunke AA, Pandya SJ, Gandhi JS, Parikh AR. Malignant peripheral nerve sheath tumor with analysis of various prognostic factors: A single-institutional experience. J Cancer Res Ther. 2021;17:106\u201313.","journal-title":"J Cancer Res Ther"},{"key":"4460_CR37","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ejca.2015.12.015","volume":"56","author":"T Valentin","year":"2016","unstructured":"Valentin T, Le Cesne A, Ray-Coquard I, Italiano A, Decanter G, Bompas E, et al. Management and prognosis of malignant peripheral nerve sheath tumors: The experience of the French Sarcoma Group (GSF-GETO). Eur J Cancer. 2016;56:77\u201384.","journal-title":"Eur J Cancer"},{"key":"4460_CR38","doi-asserted-by":"publisher","first-page":"e27833","DOI":"10.1002\/pbc.27833","volume":"66","author":"MM van Noesel","year":"2019","unstructured":"van Noesel MM, Orbach D, Brennan B, Kelsey A, Zanetti I, de Salvo GL, et al. Outcome and prognostic factors in pediatric malignant peripheral nerve sheath tumors: An analysis of the European Pediatric Soft Tissue Sarcoma Group (EpSSG) NRSTS-2005 prospective study. Pediatr Blood Cancer. 2019;66:e27833.","journal-title":"Pediatr Blood Cancer"},{"key":"4460_CR39","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1590\/0004-282x20170052","volume":"75","author":"RAT Vasconcelos","year":"2017","unstructured":"Vasconcelos RAT, Coscarelli PG, Alvarenga RP, Acioly MA. Malignant peripheral nerve sheath tumor with and without neurofibromatosis type 1. Arq Neuropsiquiatr. 2017;75:366\u201371.","journal-title":"Arq Neuropsiquiatr"},{"key":"4460_CR40","doi-asserted-by":"publisher","first-page":"963","DOI":"10.6061\/clinics\/2012(08)18","volume":"67","author":"KS Cunha","year":"2012","unstructured":"Cunha KS, Caruso AC, Faria PA, Silva LE, Pires AR, Geller M, et al. Malignant peripheral nerve sheath tumors: clinicopathological aspects, expression of p53 and survival. Clin (Sao Paulo). 2012;67:963\u20138.","journal-title":"Clin (Sao Paulo)"},{"key":"4460_CR41","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/S0748-7983(05)80073-3","volume":"21","author":"PF Doorn","year":"1995","unstructured":"Doorn PF, Molenaar WM, Buter J, Hoekstra HJ. Malignant peripheral nerve sheath tumors in patients with and without neurofibromatosis. Eur J Surg Oncol. 1995;21:78\u201382.","journal-title":"Eur J Surg Oncol"},{"key":"4460_CR42","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s11060-006-9266-2","volume":"82","author":"C Hagel","year":"2007","unstructured":"Hagel C, Zils U, Peiper M, Kluwe L, Gotthard S, Friedrich RE, et al. Histopathology and clinical outcome of NF1-associated vs. sporadic malignant peripheral nerve sheath tumors. J Neurooncol. 2007;82:187\u201392.","journal-title":"J Neurooncol"},{"key":"4460_CR43","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ejso.2012.09.001","volume":"39","author":"SC Kamran","year":"2013","unstructured":"Kamran SC, Howard SA, Shinagare AB, Krajewski KM, Jagannathan JP, Hornick JL, et al. Malignant peripheral nerve sheath tumors: prognostic impact of rhabdomyoblastic differentiation (malignant triton tumors), neurofibromatosis 1 status and location. Eur J Surg Oncol. 2013;39:46\u201352.","journal-title":"Eur J Surg Oncol"},{"key":"4460_CR44","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ejca.2019.10.014","volume":"124","author":"E Martin","year":"2020","unstructured":"Martin E, Coert JH, Flucke UE, Slooff WM, Ho VKY, van der Graaf WT, et al. A nationwide cohort study on treatment and survival in patients with malignant peripheral nerve sheath tumours. Eur J Cancer. 2020;124:77\u201387.","journal-title":"Eur J Cancer"},{"key":"4460_CR45","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.radonc.2019.03.015","volume":"137","author":"R Miao","year":"2019","unstructured":"Miao R, Wang H, Jacobson A, Lietz AP, Choy E, Raskin KA, et al. Radiation-induced and neurofibromatosis-associated malignant peripheral nerve sheath tumors (MPNST) have worse outcomes than sporadic MPNST. Radiother Oncol. 2019;137:61\u201370.","journal-title":"Radiother Oncol"},{"key":"4460_CR46","doi-asserted-by":"crossref","unstructured":"Kahn J, Gillespie A, Tsokos M, Ondos J, Dombi E, Camphausen K, et al. Radiation therapy in management of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. Front Oncol [Internet]. 2014;4. [cited 2025 Jan 18] Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/25452937\/.","DOI":"10.3389\/fonc.2014.00324"},{"key":"4460_CR47","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1002\/(SICI)1097-0142(19980601)82:11<2191::AID-CNCR14>3.0.CO;2-P","volume":"82","author":"HP Kourea","year":"1998","unstructured":"Kourea HP, Bilsky MH, Leung DH, Lewis JJ, Woodruff JM. Subdiaphragmatic and intrathoracic paraspinal malignant peripheral nerve sheath tumors: a clinicopathologic study of 25 patients and 26 tumors. Cancer. 1998;82:2191\u2013203.","journal-title":"Cancer"},{"key":"4460_CR48","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1245\/s10434-011-1978-7","volume":"19","author":"CC Stucky","year":"2012","unstructured":"Stucky CC, Johnson KN, Gray RJ, Pockaj BA, Ocal IT, Rose PS, et al. Malignant peripheral nerve sheath tumors (MPNST): the Mayo Clinic experience. Ann Surg Oncol. 2012;19:878\u201385.","journal-title":"Ann Surg Oncol"},{"key":"4460_CR49","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1097\/00000478-199207000-00008","volume":"16","author":"JM Meis","year":"1992","unstructured":"Meis JM, Enzinger FM, Martz KL, Neal JA. Malignant peripheral nerve sheath tumors (malignant schwannomas) in children. Am J Surg Pathol. 1992;16:694\u2013707.","journal-title":"Am J Surg Pathol"},{"key":"4460_CR50","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3233\/CBM-181572","volume":"24","author":"MA Krawczyk","year":"2019","unstructured":"Krawczyk MA, Karpinsky G, Izycka-Swieszewska E, Gabrych A, Kunc M, Fatyga A, et al. Immunohistochemical assessment of cyclin D1 and p53 is associated with survival in childhood malignant peripheral nerve sheath tumor. Cancer Biomark. 2019;24:351\u201361.","journal-title":"Cancer Biomark"},{"key":"4460_CR51","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s12094-013-1061-x","volume":"16","author":"Q Fan","year":"2014","unstructured":"Fan Q, Yang J, Wang G. Clinical and molecular prognostic predictors of malignant peripheral nerve sheath tumor. Clin Transl Oncol. 2014;16:191\u20139.","journal-title":"Clin Transl Oncol"},{"key":"4460_CR52","doi-asserted-by":"publisher","first-page":"e28138","DOI":"10.1002\/pbc.28138","volume":"67","author":"E Martin","year":"2020","unstructured":"Martin E, Coert JH, Flucke UE, Slooff WM, van de Sande MAJ, van Noesel MM, et al. Neurofibromatosis-associated malignant peripheral nerve sheath tumors in children have a worse prognosis: A nationwide cohort study. Pediatr Blood Cancer. 2020;67:e28138.","journal-title":"Pediatr Blood Cancer"},{"key":"4460_CR53","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.suronc.2020.09.011","volume":"35","author":"P Sobczuk","year":"2020","unstructured":"Sobczuk P, Teterycz P, Czarnecka AM, \u015awitaj T, Kose\u0142a-Paterczyk H, Kozak K, et al. Malignant peripheral nerve sheath tumors - Outcomes and prognostic factors based on the reference center experience. Surg Oncol. 2020;35:276\u201384.","journal-title":"Surg Oncol"},{"key":"4460_CR54","first-page":"86","volume":"33","author":"K Wakeman","year":"2020","unstructured":"Wakeman K, Ricciotti R, Mantilla J. Correlation between fnclcc grading and clinical outcomes in Malignant Peripheral Nerve Sheath Tumors (MPNST). Mod Pathol. 2020;33:86\u20137.","journal-title":"Mod Pathol"},{"key":"4460_CR55","doi-asserted-by":"publisher","first-page":"319","DOI":"10.3171\/2015.12.JNS152443","volume":"126","author":"KL Watson","year":"2017","unstructured":"Watson KL, Al Sannaa GA, Kivlin CM, Ingram DR, Landers SM, Roland CL, et al. Patterns of recurrence and survival in sporadic, neurofibromatosis Type 1-associated, and radiation-associated malignant peripheral nerve sheath tumors. J Neurosurg. 2017;126:319\u201329.","journal-title":"J Neurosurg"},{"key":"4460_CR56","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1097\/JCMA.0000000000000930","volume":"86","author":"Y-W Chang","year":"2023","unstructured":"Chang Y-W, Liao W-C. Survival analysis of malignant peripheral nerve sheath tumor: Experience of a tertiary center in Taiwan. J Chin Med Assoc. 2023;86:584\u20138.","journal-title":"J Chin Med Assoc"},{"key":"4460_CR57","first-page":"vdad156","volume":"5","author":"L Zhang","year":"2023","unstructured":"Zhang L, Lemberg KM, Calizo A, Varadhan R, Siegel AH, Meyer CF, et al. Analysis of treatment sequence and outcomes in patients with relapsed malignant peripheral nerve sheath tumors. Neurooncol Adv. 2023;5:vdad156.","journal-title":"Neurooncol Adv"},{"key":"4460_CR58","doi-asserted-by":"crossref","unstructured":"Cai Z, Tang X, Liang H, Yang R, Yan T, Guo W. Prognosis and risk factors for malignant peripheral nerve sheath tumor: a systematic review and meta-analysis [Internet]. World J Surg Oncol. BioMed Central Ltd. 2020. Available from: \/\/pmc\/articles\/PMC7528472\/.","DOI":"10.21203\/rs.3.rs-42720\/v1"},{"key":"4460_CR59","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12957-023-03296-z","volume":"22","author":"Z Lim","year":"2024","unstructured":"Lim Z, Gu TY, Tai BC, Puhaindran ME. Survival outcomes of malignant peripheral nerve sheath tumors (MPNSTs) with and without neurofibromatosis type I (NF1): a meta-analysis. World J Surg Oncol. 2024;22:14.","journal-title":"World J Surg Oncol"},{"key":"4460_CR60","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1215\/15228517-2008-127","volume":"11","author":"HR Brekke","year":"2009","unstructured":"Brekke HR, Kolberg M, Skotheim RI, Hall KS, Bjerkehagen B, Risberg B, et al. Identification of p53 as a strong predictor of survival for patients with malignant peripheral nerve sheath tumors. Neuro Oncol. 2009;11:514\u201328.","journal-title":"Neuro Oncol"},{"issue":"Supplement1","key":"4460_CR61","doi-asserted-by":"publisher","first-page":"i40","DOI":"10.1093\/noajnl\/vdz047","volume":"2","author":"BC Prudner","year":"2020","unstructured":"Prudner BC, Ball T, Rathore R, Hirbe AC. Diagnosis and management of malignant peripheral nerve sheath tumors: Current practice and future perspectives. Neuro-Oncology Adv. 2020;2(Supplement1):i40\u20139.","journal-title":"Neuro-Oncology Adv"},{"issue":"20","key":"4460_CR62","doi-asserted-by":"publisher","first-page":"17739","DOI":"10.1007\/s00432-023-05449-9","volume":"149","author":"S Roohani","year":"2023","unstructured":"Roohani S, Cla\u00dfen NM, Ehret F, Jarosch A, Dziodzio T, Fl\u00f6rcken A, et al. The role of radiotherapy in the management of malignant peripheral nerve sheath tumors: a single-center retrospective cohort study. J Cancer Res Clin Oncol. 2023;149(20):17739\u201347.","journal-title":"J Cancer Res Clin Oncol"},{"key":"4460_CR63","doi-asserted-by":"crossref","unstructured":"Valentin T, Le Cesne A, Ray-Coquard I, Italiano A, Decanter G, Bompas E, et al. Management and prognosis of malignant peripheral nerve sheath tumors: the experience of the French Sarcoma Group (GSF-GETO). Eur J Cancer. 2016:77\u201384.","DOI":"10.1016\/j.ejca.2015.12.015"},{"key":"4460_CR64","doi-asserted-by":"crossref","unstructured":"Martin E, Coert JH, Flucke UE, Slooff WBM, Ho VKY, van der Graaf, et al. A nationwide cohort study on treatment and survival in patients with malignant peripheral nerve sheath tumours. Eur J Cancer. 2020:77\u201387.","DOI":"10.1016\/j.ejca.2019.10.014"},{"key":"4460_CR65","doi-asserted-by":"crossref","unstructured":"hileri M, Miceli R, Fiore M, Mariani L, Ferrari A, Mussi C, et al. Malignant peripheral nerve sheath tumors: prognostic factors and survival in a series of patients treated at a single institution. Cancer. 2006;(5);1065\u20131074.","DOI":"10.1002\/cncr.22098"},{"key":"4460_CR66","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3109\/17453674.2014.908341","volume":"85","author":"K Maretty-Nielsen","year":"2014","unstructured":"Maretty-Nielsen K, Aggerholm-Pedersen N, Safwat A, Jorgensen PH, Hansen BH, Baerentzen S, et al. Prognostic factors for local recurrence and mortality in adult soft tissue sarcoma of the extremities and trunk wall: A cohort study of 922 consecutive patients. Acta Orthop. 2014;85:323.","journal-title":"Acta Orthop"},{"issue":"9","key":"4460_CR67","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1002\/ajmg.a.62890","volume":"188","author":"WY Ho","year":"2022","unstructured":"Ho WY, Farrelly E, Stevenson DA. Evaluation of the impact of the 2021 revised Neurofibromatosis type 1 diagnostic criteria on time to diagnosis. Am J Med Genet A. 2022;188(9):2584\u20139.","journal-title":"Am J Med Genet A"},{"key":"4460_CR68","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1038\/s41436-021-01170-5","volume":"8","author":"E Legius","year":"2021","unstructured":"Legius E, Messiaen L, Wolkenstein P, Pancza P, Avery RA, Berman Y, et al. Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genet Med. 2021;8:1506\u201313.","journal-title":"Genet Med"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-026-04460-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04460-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04460-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T01:02:52Z","timestamp":1788138172000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-026-04460-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4460"],"URL":"https:\/\/doi.org\/10.1186\/s13023-026-04460-w","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"assertion":[{"value":"3 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interest.","order":3,"name":"Ethics","label":"Competing interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"307"}}